Q1-FY24 · Raymond Dore
We are maintaining that guidance in full. As Dr. Raghuvanshi said, it is a good start in terms of revenue. Profitability is slightly on the lower side, but we expect to pick up the pace in the forthcoming quarters.
FORTIS / language trends
Read confidence between the lines.
Fortis Healthcare · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY24 · Anurag Kalra
Nursing is a challenge for the entire industry, and this challenge remains. ... We will see this kind of stress for next 3 to 4 years going forward as well.
Q1-FY24 · Anurag Kalra
We can easily target 1% at least on the staff cost over a period of 2 years.
Q1-FY25 · Ashutosh Raghuvanshi
Our performance in Q1 financial year 2025 has been impressive, showing a significant improvement over the previous year.
Q1-FY25 · Vivek Goyal
We have started the process of going right as per agreement, because IPO process not looking like we will be able to start immediately.
Q1-FY25 · Anand K.
We expect to be back on track in terms of growth expectations.
Q1-FY26 · Ashutosh Raghuvanshi
We have witnessed a healthy start to the financial year 2026. Our hospital business continues to perform well, both in terms of revenue and margins.
Q1-FY26 · Ashutosh Raghuvanshi
These facilities have a good potential. They are located well in the micromarkets they are in. We believe that the full potential of these hospitals has not yet been realized.
Q1-FY26 · Vivek Kumar Goyal
We are sticking to our guidance, which we have provided in the beginning of the year, 2% margin improvement. We are excited with the first quarter number.
Q2-FY24 · Ashutosh Raghuvanshi
Our guidance is absolutely intact for next year.
Q2-FY24 · Ashutosh Raghuvanshi
We are not leveraged at all. So we have a huge capacity, plus most of the CapEx, which is going to come for the brownfield expansion, 50% of it is from internal accruals and only 50% is on debt.
Q2-FY24 · Vivek Goyal
I am expecting EBITDA margin of at least 30%-35% on this revenue brownfield expansion.
Q2-FY25 · Ashutosh Raghuvanshi
Our consolidated operating EBITDA increased 31.9% to INR 435 crore, delivering a margin of 21.9% versus 18.6% in Q2 of Financial Year 24.
Q2-FY25 · Vivek Kumar Goyal
We are maintaining our margin guidelines. And when we have given that guideline, we have factored in these losses of Manesar, which is obvious because it is a sort of greenfield project.
Q2-FY25 · Anand K
In another 15 to 18 months, we should be able to be in the range of about 25%-26% kind of margins.
Q2-FY26 · Ashutosh Raghuvanshi
We expect we will continue to do better on the margin expansion side as our units are becoming matured.
Q2-FY26 · Anand Angadi
I think the target is not very far away. I will put it that way. I will not like to give any definitive timeline, but yeah, next couple of years, it is definitely looking like we are reaching there.
Q2-FY26 · Vivek Kumar Goyal
There is always a sort of hesitancy because of the non-predictability about the payment. It is always a question mark when the money will be coming, the deductions, and all those stuff.
Q3-FY24 · Ashutosh Raghuvanshi
Our business performance in Q3 has been satisfactory considering the seasonal impact of festivals in some of our key geographies.
Q3-FY24 · Vivek Goyal
We are maintaining our margin guidance, that slowly, as we know, this ramp up will happen with the bed expansion. By next three to four years, we should be aiming towards 25%.
Q3-FY24 · Vivek Goyal
The price increase is mainly attributable toward the specialty mix change and the type of procedures we are doing, which is the high-end procedures.
Q3-FY25 · Ashutosh Raghuvanshi
Our consolidated operating EBITDA increased 32% to INR 375 crores, delivering a margin of 19.4% versus 16.9% in Q3 of Financial Year 2024.
Q3-FY25 · Vivek Goyal
We are targeting margin expansion, and hopefully, we'll be seeing margin improvement year on year. Our ultimate target is to reach 25% sooner than later.
Q3-FY25 · Anand Kuppuswamy
We are seeing consistent changes and improvements on a quarter-to-quarter basis. Every quarter, we are seeing that compared to the previous quarter.
Q3-FY26 · Vivek Goyal
We feel there is still scope for margin improvement, especially with the brownfield expansion.
Q3-FY26 · Vivek Goyal
Fortis is their growth engine for India, and I think they will like to infuse fresh equity.
Q3-FY26 · Ashutosh Raghuvanshi
We are doing direct marketing there, and opening some information centers in these geographies to increase this business.
Q4-FY24 · Ashutosh Raghuvanshi
We are maintaining our guidance which we have given earlier. We could demonstrate around 2% EBITDA margin improvement over the last year. I am expecting similar type of slightly better than this in the next financial year.
Q4-FY24 · Ashutosh Raghuvanshi
We are working with the private equity investor to come out with a solution for this particular thing. So, one option is for the revival of the IPO, so that we are working with bankers along with the private equity investors for revival of the IPO.
Q4-FY24 · Ashutosh Raghuvanshi
The healthcare industry remains so much under the glare of media and public interest groups, that the industry has to calibrate the price changes very, very carefully.
Q4-FY25 · Vivek Goyal
We expect the margin to grow from the current level. Similar growth you can expect in the forthcoming years also, like 2% growth we have seen in the current financial year. Similar margin expansion growth we are expecting next financial year.
Q4-FY25 · Vivek Goyal
We are aiming around 70-71% occupancy level at the overall level. Because this brownfield expansion is on the existing facility, and these hospitals anyway are operating at 80% type of occupancy level. I think we will not be facing any challenge in occupancy side.
Q4-FY25 · Ashutosh Raghuvanshi
We have not considered that when we say that we are expecting about 2% of increase in our profitability profile. These hospitals are important statistically for the long term, but in the short term, whatever guidance has been given is not considering that these hospitals have come to a 20-plus category.